Table 2 Summary of the reported CRP change and the sponsors for the studies included in the meta-analysis on the short-term effect of fenofibrate on CRP
Index | Country | Study Name | Baseline CRP (mg/L)†| Post-treatment CRP (mg/L)†| Sponsor |
|---|---|---|---|---|---|
1 | Korea | Kim et al., 2006 [40] | 1.74 ± 1.74 | 1.54 ± 1.66 | No mention |
2 | UK | Fegan et al., 2005 [17] | 3.27 ± 1.71 | 4.03 ± 3.13 | Bayer pharmaceuticals |
3 | Poland | Undas et al. 2005 [41] | 2.33 ± 2.81 | 1.45 ± 1.41 | Polish committee for scientific research and Merck Sharp & Dohme & Fournier Laboratories |
4 | Slovenia | Sebestjen et al., 2004 [42] | 1.60 (1.10, 3.30)* | 1.10 (0.70, 2.70)* | No mention |
5 | Taiwan | Wang et al.,2003 [43] | 1.70 (0.90, 2.30)* | 1.30 (0.70, 2.00)* | National Taiwan University Hospital, National Science Council and the Academia Sinica (China) |
6 | Korea | Wi et al., 2010 [15] | 1.20 (0.43, 3.86)* | 0.90 (0.30, 4.86)* | Ministry of Health and welfare (Korea), R&BD program (Korea) and Cardiovascular Research Center (Korea) |
7 | Poland | Krysiak et al., 2010 [44] | 2.4 ± 1.56 | 1.20 ± 0.78 | Committee of Scientific Research |
8 | Poland | Krysiak et al., 2010 [44] | 1.70 ± 0.87 | 0.90 ± 0.44 | Committee of Scientific Research |
9 | USA-MI | Rosenson et al., 2010 [45] | 2.60 (1.40, 3.10)* | 1.90 (1.10, 2.60)* | Abbott Laboratories |
10 | USA-TX | Belfort et al. 2010 [46] | 6.50 ± 6.00 | 3.60 ± 3.60 | Veterans Admission Research Career development award, Howard Hughes Medical Institute, the Veterans Affairs Medical Research Fund and the National Center for Research Resources |
11 | Poland | Pruski et al., 2009 [24] | 2.8 ± 1.10 | 1.90 ± 2.19 | Medical University of Silesia |
12 | USA-UT | Muhlestein et al., 2006 [13] | 1.99** | 1.45** | No mention |
13 | Poland | Okopien et al., 2006 [32] | 2.6 ± 1.27 | 1.95 ± 1.27 | Medical University of Silesia |
14 | Canada | Hogue et al., 2008 [18] | 2.97 ± 3.29 | 2.86 ± 3.58 | Pfizer |